A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above
Latest Information Update: 06 Mar 2024
At a glance
- Drugs COVID-2019 vaccine-LIAONINGMAOKANGYUAN Biotech/ZHONGYI ANKE Biotech (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 28 Mar 2022 Planned End Date changed from 30 Jun 2022 to 30 Jul 2022.
- 28 Mar 2022 Planned primary completion date changed from 30 Jul 2021 to 30 Jul 2022.
- 26 Mar 2021 New trial record